| Project/Area Number |
25670256
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
KASUYA Yoshitoshi 千葉大学, 医学(系)研究科(研究院), 准教授 (70221877)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 多発性硬化症 / 実験的自己免疫性脳脊髄炎 / p38 / エンドセリン / リン酸化酵素 / EAE / 発症メカニズム / 細胞内リン酸化酵素 / p38MAPK |
|---|
| Outline of Final Research Achievements |
To research new therapeutic targets in multiple sclerosis, experimental autoimmune encephalomyelitis was conducted, and the following results were obtained. (1) Using p38α+/- mice resistant to the pathogenesis of EAE, plausible candidates involved in the development of EAE were evaluated. A DNA array analysis with the spinal cord samples showed that a significant difference in mRNA expression of sphingosine kinase 1, urokinase receptor, Ask2, Hexokinase 3 and STK32A was observed between WT and p38α+/- mice. (2) A bioactive substance, endothelin (ET) can regulate IL-17 production in Th17 cells through ETA receptor.
|
